<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33269798</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2048-7207</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of the Pediatric Infectious Diseases Society</Title><ISOAbbreviation>J Pediatric Infect Dis Soc</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial.</ArticleTitle><Pagination><StartPage>440</StartPage><EndPage>447</EndPage><MedlinePgn>440-447</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jpids/piaa129</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Sinovac enterovirus 71 (EV71) vaccine has been given to children aged 6-35 months with good safety, immunogenicity, and efficacy. Further exploration is needed for the application of Sinovac EV71 vaccine in older children.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A phase III, double-blind, single-center, randomized, controlled, non-inferiority, and bridging-designed trial enrolled 300 participants aged 6-35 months and 600 participants aged 36-71 months. Non-inferiority and superiority analyses were made to determine the immunogenicity of Sinovac EV71 vaccine in older children (Older-S group), comparing with that of control EV71 vaccine in the same age group (Older-C group), or comparing with that of Sinovac EV71 vaccine in younger children (Younger-S group).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The seroconversion rate of anti-EV71 in Older-S group (95.5%) was superior to that of Older-C group (86.0%), and non-inferior to that of Younger-S group (98.5%). For baseline seronegative participants, the geometric mean titer of Older-S group (370.0) was non-inferior to that of Older-C group (296.2) and superior to that of Younger-S group (176.5). Incidence of adverse reactions in Older-S group (47.0%) was similar to that of Older-C group (44.8%), or Younger-S group (49.8%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study showed good safety and immunogenicity of Sinovac EV71 vaccine in children aged 36-71 months.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT03909074.</AbstractText><AbstractText Label="URL" NlmCategory="UNASSIGNED">https://clinicaltrials.gov/ct2/show/NCT03909074?term=NCT03909074&amp;draw=2&amp;rank=1.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lifen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Yunnan Center for Disease Control and Prevention, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sinovac Biotech Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Yunnan Center for Disease Control and Prevention, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Taotao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sinovac Biotech Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shuangmin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Yunnan Center for Disease Control and Prevention, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Sinovac Biotech Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoqiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Yunnan Center for Disease Control and Prevention, Kunming, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03909074</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pediatric Infect Dis Soc</MedlineTA><NlmUniqueID>101586049</NlmUniqueID><ISSNLinking>2048-7193</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Sinovac enterovirus 71 vaccine</Keyword><Keyword MajorTopicYN="N">children aged 36&#x2013;71 months</Keyword><Keyword MajorTopicYN="N">hand, foot, and mouth disease</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>3</Day><Hour>8</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33269798</ArticleId><ArticleId IdType="doi">10.1093/jpids/piaa129</ArticleId><ArticleId IdType="pii">6017803</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>